From Feuerstein's article today
"The key question for the ASCO presentation: What's the actual survival benefit in the Zytiga "302" study? The line of demarcation is four months -- that's the survival benefit of Dendreon's Provenge in basically the same prostate cancer patient population. If Zytiga's survival benefit is greater than 4 months (let's call it 5-7 months) J&J and Medivation win and Dendreon loses.
If the survival benefit of Zytiga comes in lower than Provenge, Dendreon wins and J&J and Medivation lose."
I believe Jerzee posted a tweet from BSR that said if the 302 trial has a survival benefit greater than 4 months but wasn't statistically significant in a 1,000 patient trial, that something was wrong with the trial. Any thoughts on this?